Jonathan Hovda, MD
Pulmonary Disease · Minneapolis, MNNPI 1689836942
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Johnson & Johnson at 56.2% of the total. Reporting peaked in 2019 at $32,481 and has fallen 63.1% since, to $11,979 in 2025. Among pulmonary disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $517.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$78K
- Intuitive Surgical$19K
- Elucent Medical$15K
- Medtronic$9K
- Ethicon Endo-surgery Inc.$8K
- Medical Device Business Services, Inc.$6K
- plus $5K from 17 others
Across 32 payments — averaging $17,940 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Galvanize Therapeutics, Inc$421K
- Johnson & Johnson$109K
- Ethicon Endo-surgery Inc.$44K
What the payments were for
- Consulting fees$83,31360%
- Speaking & faculty fees$16,66012%
- Travel & lodging$30,24922%
- Food & beverage$5,4894%
- Education$3,5163%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 95 | $78,288 |
| Intuitive Surgical | 76 | $18,888 |
| Elucent Medical | 9 | $14,545 |
| Medtronic | 22 | $8,544 |
| Ethicon Endo-surgery Inc. | 19 | $7,600 |
| Medical Device Business Services, Inc. | 3 | $6,072 |
| Siemens Medical Solutions USA, Inc. | 3 | $1,512 |
| Pulmonx Corporation | 8 | $1,489 |
| Covidien LP | 2 | $1,112 |
| Galvanize Therapeutics, Inc | 10 | $402 |
| Auris Health, Inc. | 3 | $188 |
| Optellum Ltd | 1 | $150 |
| Olympus America Inc. | 3 | $125 |
| Janssen Research & Development, LLC | 2 | $60 |
| Imbio Inc. | 1 | $57 |
| Philips North America LLC | 3 | $45 |
| Pinnacle Biologics, Inc | 2 | $44 |
| Boehringer Ingelheim | 2 | $32 |
| GSK | 1 | $22 |
| Insmed, Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Mylan Specialty L.p. | 1 | $14 |
| Veran Medical Technologies, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$56,659
- MONARCH$32,143
- Da Vinci Surgical System$14,027
- ILLUMISITE$4,243
- ION$3,000
- Neuwave$1,814
- superDimension$1,103
- Pulmonx Endobronchial Valve EBV$910
- DA VINCI SP$704
- CHARTIS CATHETER$426
- ZEPHYR DELIVERY CATHETER$426
- ZEPHYR ENDOBRONCHIAL VALVE$426
- PULMONX CHARTIS TABLET CONSOLE$426
- ALIYA SYSTEM$124
How this compares
$139,228 in reported general payments places this provider in the 95th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 249 | $314,231 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 210 | $153,738 |
| Breo ElliptaFluticasone/Vilanterol | 155 | $108,112 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $65,202 |
| Spiriva RespimatTiotropium Bromide | 76 | $60,453 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 67 | $60,364 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $30,198 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 121 | $27,994 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 56 | $22,248 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $21,931 |
| Arnuity ElliptaFluticasone Furoate | 47 | $17,786 |
| DuleraMometasone/Formoterol | 23 | $17,128 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $16,940 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 30 | $15,188 |
| Serevent DiskusSalmeterol Xinafoate | 14 | $13,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $22 | $624,065699 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat, Striverdi Respimat | $32 | $134,024173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 261 pulmonary disease providers in Minnesota.
Other pulmonary disease in Minneapolis
- Marshall HertzMinneapolis$289K
- David IngbarMinneapolis$272K
- Hyun KimMinneapolis$77K
- Grady HedstromMinneapolis$50K
- Joseph KeenanMinneapolis$37K
- Mitchell KayeMinneapolis$24K
- Jennifer WongMinneapolis$12K
- Patrick WrightMinneapolis$10K
- Abdallah AbboudMinneapolis$9K
- Abbie BegnaudMinneapolis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.